GO:0034682 integrin alphav-beta1 complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034682 (integrin alphav-beta1 complex) is a heterodimeric cell-surface adhesion receptor composed of one ITGAV (alphav) subunit and one ITGB1 (beta1) subunit.
• The complex is a receptor for extracellular matrix ligands including tenascin-C, and ligand binding can trigger epithelial-mesenchymal transition-like changes in breast cancer cells.
• Integrin alphav-beta1 signaling intersects with intracellular kinase cascades such as FAK and mTOR/AKT, linking adhesion to proliferation and survival programs.
• The complex participates in astrocyte activation by filamentous Tau, implicating it in neuroinflammatory and neurodegenerative mechanisms.
• Integrin expression, including beta1-containing heterodimers, is modulated by ion channels such as TRPM2 and influences neuroblastoma migration and invasion.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of ITGAV/ITGB1 function in adhesion, signaling, and disease.
Description
The integrin alphav-beta1 complex (GO:0034682) is a cellular-component term describing a heterodimeric integrin receptor that comprises one alphav (ITGAV) subunit and one beta1 (ITGB1) subunit. Integrins are transmembrane adhesion receptors that connect the extracellular matrix to the intracellular cytoskeleton and signaling machinery, and the alphav-beta1 heterodimer is one of several alphav- or beta1-containing integrin pairs with distinct ligand specificity and tissue distribution. Because the complex sits at the interface between the cell and its environment, it is positioned to influence adhesion, migration, proliferation, and differentiation across many cell types. Experimental evidence shows that alphav-beta1 can bind tenascin-C and thereby induce epithelial-mesenchymal transition-like changes in breast cancer cells, directly linking this specific heterodimer to a phenotypic program relevant to tumor progression. Beyond matrix binding, beta1-containing integrins cross-communicate with intracellular kinase pathways such as mTOR/AKT and the CDK-cyclin axis in hepatocellular carcinoma cells, indicating that the complex is not merely a structural adhesion unit but a signaling hub. In parallel, beta1 integrin signaling has been connected to FAK-dependent control of progenitor cell growth and energy balance, underscoring its broad physiological reach. For researchers, GO:0034682 provides a precise annotation target: it distinguishes the alphav-beta1 heterodimer from other alphav or beta1 complexes and enables focused interrogation of its assembly, ligand interactions, and downstream effectors. Understanding this complex is therefore relevant to cancer biology, neurobiology, and stem/progenitor cell research, and it motivates the use of CRISPR-based models to test causality.
integrin alphav-beta1 complex At A Glance
| GO ID | GO:0034682 |
|---|---|
| GO term | integrin alphav-beta1 complex |
| Ontology | cellular_component |
| Synonym | alphav-beta1 integrin complex; ITGAV-ITGB1 complex |
| Definition | An integrin complex that comprises one alphav subunit and one beta1 subunit. |
| Major function | Heterodimeric cell-surface adhesion receptor for extracellular matrix ligands that also transmits intracellular signals. |
| Subunit composition | One ITGAV (alphav) subunit and one ITGB1 (beta1) subunit. |
| Representative ligand | Tenascin-C, which can induce epithelial-mesenchymal transition-like changes in breast cancer cells. |
| Associated signaling | FAK signaling and mTOR/AKT with CDK-cyclin regulation have been linked to beta1-containing integrin biology. |
| Disease relevance | Implicated in cancer progression, neuroinflammation, and neuroblastoma invasion through integrin-dependent mechanisms. |
What Is GO:0034682?
GO:0034682, the integrin alphav-beta1 complex, is defined as an integrin complex that comprises one alphav subunit and one beta1 subunit. In practice, this means a non-covalent heterodimer of the ITGAV (alphav) and ITGB1 (beta1) proteins at the cell surface, which functions as a receptor for extracellular matrix ligands and as a signaling platform. The term is a cellular-component annotation, so it describes where and in what molecular assembly a process occurs rather than a catalytic activity itself. Synonyms include alphav-beta1 integrin complex and ITGAV-ITGB1 complex.
Why Is integrin alphav-beta1 complex Important in Cell Biology?
The integrin alphav-beta1 complex matters because it is a defined molecular entity that couples the extracellular matrix to intracellular signaling, and its specific composition determines which ligands are recognized and which downstream pathways are engaged. Studies of beta1-containing integrins have revealed cross-communication with mTOR/AKT and cell-cycle regulators in cancer cells, while beta1 integrin signaling through FAK controls progenitor cell growth and energy balance. The complex has also been implicated in astrocyte activation by filamentous Tau and in neuroblastoma migration and invasion, extending its relevance beyond oncology into neuroscience and developmental biology. Because GO:0034682 names a precise heterodimer rather than a generic integrin category, it supports rigorous, reproducible annotation and experimental design.
• Provides a precise annotation for the ITGAV-ITGB1 heterodimer, distinguishing it from other alphav or beta1 integrin complexes.
• Functions as a receptor for tenascin-C and can drive epithelial-mesenchymal transition-like changes in breast cancer cells.
• Connects extracellular matrix adhesion to intracellular kinase signaling, including mTOR/AKT and CDK-cyclin regulation in hepatocellular carcinoma cells.
• Beta1 integrin signaling through FAK has been linked to control of beige fat progenitor cell growth and energy balance.
• Participates in filamentous Tau-induced activation of primary astrocytes, linking the complex to neuroinflammatory mechanisms.
• Integrin expression relevant to alphav-beta1 biology is modulated by the ion channel TRPM2 and affects neuroblastoma migration and invasion.
• Serves as a tractable target for CRISPR knockout, point-mutation, knock-in, and overexpression studies of adhesion and signaling.
• Relevant across cancer biology, neurobiology, and stem/progenitor cell research, supporting interdisciplinary investigation.
What Happens During integrin alphav-beta1 complex?
Subunit Assembly and Heterodimer Formation
In simple terms: Two different protein chains, alphav and beta1, pair up to form one functional receptor.
The integrin alphav-beta1 complex is defined by the non-covalent association of one alphav (ITGAV) subunit with one beta1 (ITGB1) subunit, forming a heterodimeric receptor at the cell surface. This assembly is the defining feature of GO:0034682 and distinguishes it from other integrin heterodimers that use different alpha or beta subunits. The pairing dictates ligand specificity and signaling output, so the identity of the beta1 partner is functionally important.
Ligand Recognition and Matrix Engagement
In simple terms: The assembled receptor grabs onto specific proteins in the space around the cell.
The alphav-beta1 complex can bind extracellular matrix ligands such as tenascin-C, and this interaction is sufficient to induce epithelial-mesenchymal transition-like changes in breast cancer cells. Ligand engagement is the initiating event that converts the complex from an adhesion molecule into a signal-transducing receptor. Because different integrin heterodimers recognize different matrix proteins, the alphav-beta1 pair confers a specific ligand-binding profile.
Downstream Signaling and Phenotypic Change
In simple terms: Once the receptor binds, it switches on internal signals that change how the cell behaves.
Beta1-containing integrins cross-communicate with mTOR/AKT and the CDK-cyclin axis in hepatocellular carcinoma cells, linking adhesion to proliferation and survival programs. In a separate context, beta1 integrin signaling through FAK controls beige fat progenitor cell growth and energy balance, showing that the downstream consequences are cell-type dependent. These findings indicate that the alphav-beta1 complex functions as a signaling hub rather than a passive structural element.
Regulation by Cellular Context and Ion Channels
In simple terms: Other proteins in the cell can change how much integrin is present or how active it is.
The human ion channel TRPM2 modulates migration and invasion in neuroblastoma through regulation of integrin expression, demonstrating that integrin levels and activity are subject to upstream control. This context dependence means that the functional output of the alphav-beta1 complex can vary with the cellular environment and the presence of regulatory proteins. Such regulation is relevant when interpreting experiments that manipulate integrin subunits directly.
Roles in Neuroinflammation and Glial Activation
In simple terms: In the brain, this receptor can help trigger an inflammatory response in support cells.
Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex, implicating integrin-dependent signaling in astrocyte responses relevant to neurodegeneration. This observation extends the biological reach of integrin complexes beyond classical adhesion and cancer biology into neuroinflammatory mechanisms. It also suggests that perturbing specific integrin heterodimers could modulate glial activation states.
Key Genes Involved in GO:0034682 integrin alphav-beta1 complex
The following genes and proteins are directly or functionally connected to the integrin alphav-beta1 complex (GO:0034682) in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ITGAV | Encodes the alphav subunit of the integrin alphav-beta1 heterodimer | Defines the alpha chain of GO:0034682 and determines ligand specificity |
| ITGB1 | Encodes the beta1 subunit of the integrin alphav-beta1 heterodimer | Defines the beta chain of GO:0034682 and links to FAK and mTOR/AKT signaling |
| FAK (PTK2) | Non-receptor tyrosine kinase downstream of beta1 integrin signaling | Mediates beta1 integrin-dependent control of progenitor cell growth and energy balance |
| mTOR | Kinase in the mTOR/AKT pathway that cross-communicates with beta1 integrins | Links integrin signaling to proliferation and survival in hepatocellular carcinoma cells |
| AKT | Serine/threonine kinase in the mTOR/AKT axis | Participates in beta1 integrin cross-communication with growth and cell-cycle pathways |
| CDK-cyclin axis | Cell-cycle regulatory machinery | Cross-communicates with beta1 integrin signaling in hepatocellular carcinoma cells |
| TRPM2 | Human ion channel that modulates integrin expression | Regulates migration and invasion in neuroblastoma through integrin expression |
| Tenascin-C (TNC) | Extracellular matrix ligand for alphav-beta1 and alphav-beta6 integrins | Binding to alphav-beta1 induces epithelial-mesenchymal transition-like changes in breast cancer cells |
| Tau (MAPT) | Microtubule-associated protein that can form filamentous aggregates | Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex |
| CD81 | Tetraspanin that controls beige fat progenitor cell growth via FAK signaling | Provides context for FAK-dependent, integrin-linked progenitor cell regulation |
| MMP-3 | Matrix metalloproteinase acting sequentially with integrin and EMMPRIN | Implicated in integrin-linked differentiation of mouse embryonic stem cells into odontoblast-like cells |
| EMMPRIN (CD147) | Extracellular matrix metalloproteinase inducer | Acts with alpha2 integrin and MMP-3 in differentiation-related processes |
| ITGA2 | Alpha2 integrin subunit | Cross-communicates with beta1 integrin and mTOR/AKT in hepatocellular carcinoma cells |
| ITGB3 | Beta3 integrin subunit | Required for differentiation in OC-2 cells derived from mammalian embryonic inner ear |
| ITGAV-ITGB6 | Related alphav heterodimer with tenascin-C binding | Provides comparative context for alphav-beta1 ligand interactions |
| Doxazosin target pathway | Death receptor-mediated apoptosis pathway in prostate cells | Illustrates integrin-adjacent pharmacological contexts in prostate cell models |
How Is integrin alphav-beta1 complex Regulated?
The integrin alphav-beta1 complex is regulated at multiple levels. Its expression can be modulated by other membrane proteins, as shown by the ion channel TRPM2 regulating integrin expression and thereby influencing neuroblastoma migration and invasion. Downstream signaling from beta1-containing integrins cross-communicates with mTOR/AKT and the CDK-cyclin axis, indicating that the functional output of the complex is integrated with growth and cell-cycle control. In addition, beta1 integrin signaling through FAK controls progenitor cell growth and energy balance, showing that metabolic and proliferative contexts shape the consequences of integrin engagement. Ligand availability, such as tenascin-C in the extracellular matrix, further determines whether alphav-beta1 engagement drives phenotypic changes like epithelial-mesenchymal transition.
integrin alphav-beta1 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ITGAV / ITGB1 | Breast cancer epithelial-mesenchymal transition driven by tenascin-C binding | CRISPR knockout or point-mutation in breast cancer cell lines followed by EMT marker analysis |
| ITGB1 | Hepatocellular carcinoma proliferation via mTOR/AKT and CDK-cyclin cross-communication | Knockout and overexpression in hepatocellular carcinoma cells with pathway readouts |
| TRPM2 / integrins | Neuroblastoma migration and invasion through integrin expression regulation | Knockdown or knockout of TRPM2 with integrin expression and invasion assays |
| Integrin receptor complex / Tau | Astrocyte activation in tauopathy-related neuroinflammation | Primary astrocyte cultures treated with filamentous Tau and integrin-blocking or knockout approaches |
| ITGB1 / FAK | Beige fat progenitor growth and energy balance | Knockout or knock-in models in adipocyte progenitor cells with FAK signaling readouts |
Cancer Progression and Epithelial-Mesenchymal Transition
Binding of alphav-beta1 to tenascin-C induces epithelial-mesenchymal transition-like changes in breast cancer cells, directly linking this specific integrin heterodimer to a program associated with tumor progression and metastasis. In hepatocellular carcinoma cells, beta1 integrin cross-communication with mTOR/AKT and the CDK-cyclin axis connects adhesion to proliferative and survival signaling. These findings support the view that the alphav-beta1 complex contributes to cancer cell phenotypes through both matrix engagement and intracellular pathway activation.
Neuroblastoma Migration and Invasion
The human ion channel TRPM2 modulates migration and invasion in neuroblastoma through regulation of integrin expression, placing integrin-dependent adhesion in the pathway of neuroblastoma aggressiveness. Because the alphav-beta1 complex is one of the beta1-containing integrins expressed in such contexts, changes in integrin expression can alter the adhesive and invasive behavior of neuroblastoma cells. This provides a rationale for studying integrin subunits as modulators of pediatric solid tumor behavior.
Neuroinflammation and Tau Pathology
Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex, indicating that integrin-dependent signaling participates in glial responses relevant to tauopathies. This mechanism suggests that integrin complexes on astrocytes can transduce signals from aggregated Tau, potentially contributing to neuroinflammatory components of neurodegeneration. Targeting specific integrin heterodimers may therefore be explored as a strategy to modulate astrocyte activation.
Progenitor Cell Growth and Metabolic Balance
Beta1 integrin signaling through FAK controls beige fat progenitor cell growth and energy balance, demonstrating that integrin-dependent pathways influence metabolic tissue homeostasis. This connects the biology of beta1-containing integrins, including the alphav-beta1 complex, to progenitor cell expansion and systemic energy regulation. Such findings broaden the disease relevance of integrin biology beyond cancer into metabolic disorders.
From integrin alphav-beta1 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is ITGAV required for alphav-beta1-mediated adhesion and EMT-like changes? | CRISPR knockout of ITGAV in breast cancer cells followed by tenascin-C adhesion and EMT marker assays |
| Does a specific ITGB1 point mutation disrupt downstream mTOR/AKT signaling? | CRISPR point-mutation knock-in of ITGB1 in hepatocellular carcinoma cells with phospho-AKT readouts |
| Can tagged ITGB1 be used to track alphav-beta1 complex localization? | Tagged knock-in of ITGB1 with imaging and co-immunoprecipitation |
| Does overexpression of ITGAV-ITGB1 alter neuroblastoma invasion? | Overexpression of ITGAV and ITGB1 in neuroblastoma cells with migration and invasion assays |
| Does loss of beta1 integrin signaling affect progenitor growth and energy balance? | CRISPR knockout of ITGB1 in beige fat progenitor cells with FAK signaling and growth assays |
| Can integrin-dependent astrocyte activation by Tau be blocked genetically? | Knockout of candidate integrin subunits in primary astrocytes treated with filamentous Tau |
How to Study the integrin alphav-beta1 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Adhesion assay | Cell attachment to extracellular matrix ligands | Testing alphav-beta1 binding to tenascin-C in breast cancer cells |
| Western blot / phospho-protein analysis | Activation of mTOR/AKT and CDK-cyclin pathways | Assessing beta1 integrin signaling in hepatocellular carcinoma cells |
| FAK phosphorylation assay | Beta1 integrin-dependent FAK signaling | Studying progenitor cell growth and energy balance |
| Transwell migration/invasion assay | Cell migration and invasion capacity | Evaluating integrin-dependent neuroblastoma behavior |
| Primary astrocyte culture with Tau | Astrocyte activation and signaling | Modeling integrin-dependent neuroinflammation |
| CRISPR knockout | Loss-of-function phenotype | Testing requirement for ITGAV or ITGB1 in adhesion and signaling |
| CRISPR point mutation | Effect of specific amino acid changes | Dissecting ITGB1 domains required for downstream signaling |
| Tagged knock-in | Protein localization and complex composition | Tracking alphav-beta1 assembly and trafficking |
Adhesion and Ligand-Binding Assays
Adhesion assays using extracellular matrix ligands such as tenascin-C can test whether the alphav-beta1 complex mediates cell attachment and whether genetic perturbation of ITGAV or ITGB1 alters this behavior. These assays are typically combined with EMT marker analysis to connect adhesion to phenotypic change in breast cancer cells. They provide a direct functional readout for the ligand-recognition step of the complex.
Signaling Pathway Readouts
Western blotting and phospho-protein analysis can measure mTOR/AKT and CDK-cyclin pathway activity downstream of beta1 integrin signaling in hepatocellular carcinoma cells. FAK phosphorylation serves as a readout for beta1 integrin-dependent signaling in progenitor cell contexts. These methods link the presence or absence of the complex to intracellular signaling states.
Migration and Invasion Assays
Transwell migration and invasion assays are used to assess how integrin expression changes affect neuroblastoma cell behavior, particularly when upstream regulators such as TRPM2 are manipulated. Such assays connect integrin expression levels to invasive phenotypes. They are useful for testing whether alphav-beta1 contributes to migration in specific tumor backgrounds.
Astrocyte Activation and Neuroinflammation Models
Primary astrocyte cultures treated with filamentous recombinant human Tau can be used to study integrin receptor complex-dependent activation. Readouts include activation markers and signaling changes that reflect glial responses. This model connects integrin biology to neuroinflammatory mechanisms relevant to tauopathies.
How CRISPR Can Be Used to Study GO:0034682 integrin alphav-beta1 complex
Knockout
CRISPR knockout of ITGAV or ITGB1 can abolish formation of the integrin alphav-beta1 complex and test its requirement in adhesion, EMT-like changes, and downstream signaling. In hepatocellular carcinoma cells, knockout approaches help determine whether beta1 integrin is necessary for mTOR/AKT and CDK-cyclin cross-communication. In progenitor cell models, ITGB1 knockout can reveal whether beta1 integrin signaling through FAK is required for growth and energy balance.
Point Mutation
CRISPR point-mutation knock-in can introduce specific amino acid substitutions into ITGAV or ITGB1 to dissect which residues are required for ligand binding or downstream signaling. Such models are valuable when complete knockout is lethal or when domain-specific functions need to be separated. They allow precise testing of structure-function relationships within the alphav-beta1 heterodimer.
Knock-in
Knock-in of epitope tags or fluorescent reporters into ITGAV or ITGB1 enables tracking of the alphav-beta1 complex by imaging and co-immunoprecipitation. Tagged knock-in models preserve endogenous regulatory elements and can reveal where and when the complex assembles. They are also useful for proteomic identification of complex-associated proteins.
Overexpression
Overexpression of ITGAV and ITGB1 can test whether increased levels of the alphav-beta1 complex enhance adhesion, migration, or invasion in cell types such as neuroblastoma. Overexpression models complement loss-of-function studies by showing sufficiency rather than requirement. They are also useful for testing whether integrin levels are limiting for a given phenotype.
How EDITGENE Supports integrin alphav-beta1 complex Research
Researchers studying integrin alphav-beta1 complex-related genes often need to determine whether a candidate gene is causally involved in adhesion, signaling, or disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise, reproducible interrogation of ITGAV, ITGB1, and their regulatory network.
Contact EDITGENE today to design your custom CRISPR model for integrin alphav-beta1 complex research.
Frequently Asked Questions About integrin alphav-beta1 complex
What is the integrin alphav-beta1 complex (GO:0034682)?
It is a heterodimeric integrin receptor composed of one alphav (ITGAV) subunit and one beta1 (ITGB1) subunit, annotated as GO:0034682 in the cellular_component ontology.
What genes are involved in the integrin alphav-beta1 complex?
The core genes are ITGAV, encoding the alphav subunit, and ITGB1, encoding the beta1 subunit; downstream signaling involves FAK, mTOR/AKT, and CDK-cyclin components.
What ligands does the integrin alphav-beta1 complex bind?
The complex can bind tenascin-C, and this interaction induces epithelial-mesenchymal transition-like changes in breast cancer cells.
How is the integrin alphav-beta1 complex linked to cancer?
It contributes to cancer cell phenotypes through matrix engagement and intracellular signaling, including EMT-like changes in breast cancer and mTOR/AKT cross-communication in hepatocellular carcinoma.
Is the integrin alphav-beta1 complex involved in neuroinflammation?
Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex, linking integrin-dependent signaling to neuroinflammatory mechanisms.
How do researchers study the integrin alphav-beta1 complex?
Common methods include adhesion assays, signaling readouts such as phospho-AKT and FAK, migration and invasion assays, and CRISPR-based genetic perturbation.
What is the difference between alphav-beta1 and other integrin complexes?
GO:0034682 specifically describes the heterodimer of one alphav subunit and one beta1 subunit, distinguishing it from other alphav or beta1 pairings with different ligand specificity.
Can CRISPR knockout be used to study ITGAV and ITGB1?
Yes, CRISPR knockout of ITGAV or ITGB1 can abolish the complex and test its requirement in adhesion, signaling, and disease-relevant phenotypes.
What signaling pathways are downstream of beta1 integrin?
Beta1-containing integrins cross-communicate with mTOR/AKT and the CDK-cyclin axis, and beta1 integrin signaling through FAK controls progenitor cell growth and energy balance.
Why is the integrin alphav-beta1 complex important for drug discovery?
Because it links extracellular matrix adhesion to intracellular survival and proliferation pathways, it represents a potential target for modulating cancer, neuroinflammatory, and metabolic phenotypes.
Conclusion
The integrin alphav-beta1 complex (GO:0034682) is a precisely defined heterodimeric adhesion receptor that connects the extracellular matrix to intracellular signaling through pathways such as FAK and mTOR/AKT. Its involvement in epithelial-mesenchymal transition-like changes, neuroblastoma invasion, astrocyte activation, and progenitor cell growth highlights its broad biological and disease relevance. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide the causal tools needed to dissect how ITGAV and ITGB1 contribute to these phenotypes. Researchers can leverage these approaches to generate publication-ready evidence linking the alphav-beta1 complex to specific cellular behaviors and disease mechanisms.
References
- 1. Oguri Y et al.. 2020. CD81 Controls Beige Fat Progenitor Cell Growth and Energy Balance via FAK Signaling.. Cell 182(3):563-577.e20 PMID: 32615086
- 2. Juratli MA et al.. 2022. Integrin α2 and β1 Cross-Communication with mTOR/AKT and the CDK-Cyclin Axis in Hepatocellular Carcinoma Cells.. Cancers (Basel) 14(10) PMID: 35626034
- 3. Wang P et al.. 2021. Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex.. Nat Commun 12(1):95 PMID: 33398028
- 4. Bao L et al.. 2022. The human ion channel TRPM2 modulates migration and invasion in neuroblastoma through regulation of integrin expression.. Sci Rep 12(1):20544 PMID: 36446940
- 5. Katoh D et al.. 2013. Binding of αvβ1 and αvβ6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells.. Oncogenesis 2(8):e65 PMID: 23958855
- 6. Brunetta I et al.. 2012. β3-integrin is required for differentiation in OC-2 cells derived from mammalian embryonic inner ear.. BMC Cell Biol 13:5 PMID: 22424110
- 7. Ozeki N et al.. 2015. Α2 integrin, extracellular matrix metalloproteinase inducer, and matrix metalloproteinase-3 act sequentially to induce differentiation of mouse embryonic stem cells into odontoblast-like cells.. Exp Cell Res 331(1):21-37 PMID: 25194508
- 8. Garrison JB et al.. 2006. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.. Cancer Res 66(1):464-72 PMID: 16397262
